BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 26460956)

  • 1. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
    Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
    Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
    Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
    Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
    Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
    Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses.
    Bian SX; Korah MP; Whitaker TR; Ji L; Groshen S; Chung E
    Clin Breast Cancer; 2017 Nov; 17(7):510-515. PubMed ID: 28412326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
    Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
    Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Abouegylah M; Braunstein LZ; Alm El-Din MA; Niemierko A; Salama L; Elebrashi M; Edgington SK; Remillard K; Napolitano B; Naoum GE; Sayegh HE; Gillespie T; Farouk M; Ismail AA; Taghian AG
    Breast Cancer Res Treat; 2019 Feb; 174(1):179-185. PubMed ID: 30478787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
    De Santis MC; Bonfantini F; Di Salvo F; Fiorentino A; Riboldi VM; Di Cosimo S; Bianchi GV; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Lozza L
    Clin Breast Cancer; 2018 Jun; 18(3):e363-e371. PubMed ID: 28958838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
    Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy.
    Antunac K; Mayer L; Banovic M; Beketic-Oreskovic L
    Curr Oncol; 2023 Oct; 30(10):9049-9062. PubMed ID: 37887554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
    Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
    Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.